Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study.

[1]  F. Xie,et al.  Fentanyl buccal tablet for the treatment of breakthrough pain in opioid‐tolerant patients with chronic cancer pain , 2009, Cancer.

[2]  N. Slatkin,et al.  Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. , 2007, The journal of supportive oncology.

[3]  D. Simpson,et al.  Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. , 2007, Clinical therapeutics.

[4]  P. Robertson,et al.  Absolute and Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate , 2007, Journal of clinical pharmacology.

[5]  R. Portenoy,et al.  Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study* , 2007, Current medical research and opinion.

[6]  L. Tremmel,et al.  A Randomized, Placebo-controlled Study of Fentanyl Buccal Tablet for Breakthrough Pain in Opioid-treated Patients With Cancer , 2006, The Clinical journal of pain.

[7]  P. Robertson,et al.  Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. , 2006, Clinical therapeutics.

[8]  M. Darwish,et al.  Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. , 2006, Clinical therapeutics.

[9]  J. Messina,et al.  Fentanyl effervescent buccal tablets , 2006 .

[10]  E. Kalso,et al.  Breakthrough pain in malignant and non‐malignant diseases: a review of prevalence, characteristics and mechanisms , 2005, European journal of pain.

[11]  M. Darwish,et al.  Pharmacokinetics and Dose Proportionality of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers , 2005, Clinical pharmacokinetics.

[12]  F. Vandenhende,et al.  Confidence Interval Criteria for Assessment of Dose Proportionality , 2004, Pharmaceutical Research.

[13]  R. Portenoy,et al.  Breakthrough pain: definition, prevalence and characteristics , 1990, Pain.

[14]  R. Venkataramanan,et al.  Clinical Pharmacokinetics of Cyclosporin , 1986, Clinical pharmacokinetics.

[15]  S. Bower,et al.  The uptake of fentanyl by erythrocytes , 1982, The Journal of pharmacy and pharmacology.